Drugs · acquisition-cost intelligence
Ryaltris
olopatadine hydrochloride and mometasone furoate· ingredient mometasoneAntiallergic agents, excl. corticosteroids· MOMETASONE FUROATE MONOHYDRATE 25 ug/1; OLOPATADINE HYDROCHLORIDE 665 ug/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$7.69
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 4 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other mometasone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| Mometasone furoate | $0.26779 | −$7.42 |
| Mometasone Furoate | $0.34950 | −$7.34 |
| Mometasone Furoate | $0.48662 | −$7.20 |
| allergy | $1.43 | −$6.25 |
| ASMANEX HFA | $7.38 | −$0.31060 |
| Dulera | $25.23 | +$17.55 |
| ASMANEX | $104.30 | +$96.61 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.